|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
American Cancer Society. Breast Cancer
Facts and Figures. 2015, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015.
Accessed: February 9, 2016
|
|
3
|
BreastCancer.org. US Breast Cancer
Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics.
Accessed: February 9, 2016
|
|
4
|
Kimbung S, Loman N and Hedenfalk I:
Clinical and molecular complexity of breast cancer metastases.
Semin Cancer Biol. 35:85–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zardavas D, Irrthum A, Swanton C and
Piccart M: Clinical management of breast cancer heterogeneity. Nat
Rev Clin Oncol. 12:381–394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peintinger F, Sinn B, Hatzis C, Albarracin
C, Downs-Kelly E, Morkowski J, Gould R and Symmans WF:
Reproducibility of residual cancer burden for prognostic assessment
of breast cancer after neoadjuvant chemotherapy. Mod Pathol.
28:913–920. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu H, Eirew P, Mullaly SC and Aparicio S:
The omics of triple-negative breast cancers. Clin Chem. 60:122–133.
2014. View Article : Google Scholar
|
|
9
|
Lee JM, Ledermann JA and Kohn EC: PARP
Inhibitors for BRCA1/2 mutation-associated and BRCA-like
malignancies. Ann Oncol. 25:32–40. 2014. View Article : Google Scholar :
|
|
10
|
Bayraktar S and Glück S: Molecularly
targeted therapies for metastatic triple-negative breast cancer.
Breast Cancer Res Treat. 138:21–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brewster AM, Chavez-MacGregor M and Brown
P: Epidemiology, biology, and treatment of triple-negative breast
cancer in women of African ancestry. Lancet Oncol. 15:e625–e634.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carey LA, Rugo HS, Marcom PK, Mayer EL,
Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A,
et al: TBCRC 001: Randomized phase II study of cetuximab in
combination with carboplatin in stage IV triple-negative breast
cancer. J Clin Oncol. 30:2615–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anbalagan M, Moroz K, Ali A, Carrier L,
Glodowski S and Rowan BG: Subcellular localization of total and
activated Src kinase in African American and Caucasian breast
cancer. PLoS One. 7:e330172012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chavez KJ, Garimella SV and Lipkowitz S:
Triple negative breast cancer cell lines: One tool in the search
for better treatment of triple negative breast cancer. Breast Dis.
32:35–48. 2010.
|
|
15
|
Hughes L, Malone C, Chumsri S, Burger AM
and McDonnell S: Characterisation of breast cancer cell lines and
establishment of a novel isogenic subclone to study migration,
invasion and tumourigenicity. Clin Exp Metastasis. 25:549–557.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Le Du F, Eckhardt BL, Lim B, Litton JK,
Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM and Ueno NT: Is the
future of personalized therapy in triple-negative breast cancer
based on molecular subtype? Oncotarget. 6:12890–12908. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sulzmaier FJ, Jean C and Schlaepfer DD:
FAK in cancer: Mechanistic findings and clinical applications. Nat
Rev Cancer. 14:598–610. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Golubovskaya VM, Ylagan L, Miller A,
Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C,
et al: High focal adhesion kinase expression in breast carcinoma is
associated with lymphovascular invasion and triple-negative
phenotype. BMC Cancer. 14:769–777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakamura K, Yano H, Schaefer E and Sabe H:
Different modes and qualities of tyrosine phosphorylation of Fak
and Pyk2 during epithelial-mesenchymal transdifferentiation and
cell migration: Analysis of specific phosphorylation events using
site-directed antibodies. Oncogene. 20:2626–2635. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Le Boeuf F, Houle F and Huot J: Regulation
of vascular endothelial growth factor receptor 2-mediated
phosphorylation of focal adhesion kinase by heat shock protein 90
and Src kinase activities. J Biol Chem. 279:39175–39185. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim Y, Park H, Jeon J, Han I, Kim J, Jho
EH and Oh ES: Focal adhesion kinase is negatively regulated by
phosphorylation at tyrosine 407. J Biol Chem. 282:10398–10404.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeon J, Lee H, Park H, Lee JH, Choi S,
Hwang J, Han IO and Oh ES: Phosphorylation of focal adhesion kinase
at Tyrosine 407 negatively regulates Ras transformation of
fibroblasts. Biochem Biophys Res Commun. 364:1062–1066. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lie PP, Mruk DD, Mok KW, Su L, Lee WM and
Cheng CY: Focal adhesion kinase-Tyr407 and -Tyr397 exhibit
antagonistic effects on blood-testis barrier dynamics in the rat.
Proc Natl Acad Sci USA. 109:12562–12567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boivin B, Chaudhary F, Dickinson BC, Haque
A, Pero SC, Chang CJ and Tonks NK: Receptor protein-tyrosine
phosphatase α regulates focal adhesion kinase phosphorylation and
ErbB2 oncoprotein-mediated mammary epithelial cell motility. J Biol
Chem. 288:36926–36935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Humphries JD, Byron A and Humphries MJ:
Integrin ligands at a glance. J Cell Sci. 119:3901–3903. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hakomori SI: Structure and function of
glycosphingolipids and sphingolipids: Recollections and future
trends. Biochim Biophys Acta. 1780:325–346. 2008. View Article : Google Scholar
|
|
28
|
Hakomori SI and Handa K: GM3 and cancer.
Glycoconj J. 32:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taliaferro-Smith L, Oberlick E, Liu T,
McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E,
Nagaraju GP, et al: FAK activation is required for IGF1R-mediated
regulation of EMT, migration, and invasion in mesenchymal triple
negative breast cancer cells. Oncotarget. 6:4757–4772. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hartman ZR, Schaller MD and Agazie YM: The
tyrosine phosphatase SHP2 regulates focal adhesion kinase to
promote EGF-induced lamellipodia persistence and cell migration.
Mol Cancer Res. 11:651–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brunton VG, Avizienyte E, Fincham VJ,
Serrels B, Metcalf CA III, Sawyer TK and Frame MC: Identification
of Src-specific phosphorylation site on focal adhesion kinase:
Dissection of the role of Src SH2 and catalytic functions and their
consequences for tumor cell behavior. Cancer Res. 65:1335–1342.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Calalb MB, Polte TR and Hanks SK: Tyrosine
phosphorylation of focal adhesion kinase at sites in the catalytic
domain regulates kinase activity: A role for Src family kinases.
Mol Cell Biol. 15:954–963. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ciccimaro E, Hevko J and Blair IA:
Analysis of phosphorylation sites on focal adhesion kinase using
nanospray liquid chromatography/ multiple reaction monitoring mass
spectrometry. Rapid Commun Mass Spectrom. 20:3681–3692. 2006.
View Article : Google Scholar
|
|
34
|
Frame MC, Patel H, Serrels B, Lietha D and
Eck MJ: The FERM domain: Organizing the structure and function of
FAK. Nat Rev Mol Cell Biol. 11:802–814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lietha D, Cai X, Ceccarelli DF, Li Y,
Schaller MD and Eck MJ: Structural basis for the autoinhibition of
focal adhesion kinase. Cell. 129:1177–1187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mitra SK, Hanson DA and Schlaepfer DD:
Focal adhesion kinase: In command and control of cell motility. Nat
Rev Mol Cell Biol. 6:56–68. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fincham VJ, Unlu M, Brunton VG, Pitts JD,
Wyke JA and Frame MC: Translocation of Src kinase to the cell
periphery is mediated by the actin cytoskeleton under the control
of the Rho family of small G proteins. J Cell Biol. 135:1551–1564.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elsberger B, Tan BA, Mitchell TJ, Brown
SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG and Edwards J: Is
expression or activation of Src kinase associated with
cancer-specific survival in ER-, PR- and HER2-negative breast
cancer patients? Am J Pathol. 175:1389–1397. 2009. View Article : Google Scholar : PubMed/NCBI
|
